Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Rep. Joe Barton, a ranking member of the House Energy and Commerce Committee, appears to be fed up with the FDA’s reluctance to provide details of the tainted heparin scandal that first came into public light earlier this year, according to CNN Money. That scandal resulted in the deaths of more than 80 Americans and adverse reactions in hundreds more, and led to an agency recall of lots of the blood thinner manufactured in Baxter International’s Chinese facility.

Read the rest of this entry »

The sole provider of heparin in the United States, APP Pharmaceuticals LLC, has launched a Web site as a first step toward improving the safety of the medications it sells in the U.S., according to Reuters.

The Web site details the safety measures the pharmaceutical company has taken over the past several months, including enhanced labeling, unit-of-use bar codes, large lettering and color-coded bottle stoppers to help eliminate misuse of its products, which also includes injectible drugs for oncology.

Read the rest of this entry »

The Associated Press reported today that German dialysis clinic operator Fresenius has been approved to purchase APP Pharmaceuticals. APP makes injectable drugs, including heparin, and just announced its plans to begin manufacturing heparin at its Puerto Rico facility after receiving approval by the U.S. Food & Drug Administration (FDA).

Read the rest of this entry »

This week APP Pharmaceuticals, headquartered in Schaumberg, Ill., announced it has gotten FDA approval to manufacture heparin at its Barceloneta, Puerto Rico, facility. The facility will manufacture three product codes of heparin sodium injection, USP.

Read the rest of this entry »